PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors

PDS Biotechnology appointed John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to its board effective October 18, 2026, replacing four departing directors (Stephen Glover, Kamil Ali-Jackson, Gregory Freitag, Otis Brawley) on the same date. The three new directors bring pharma operating backgrounds in drug development, regulatory affairs, and M&A/business development, with committee assignments already set (Banaag chairs Audit; Soon-Shiong chairs Compensation; Wendel chairs Nominating). Management tied the new directors' skillset to two near-term priorities: advancing PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursuing a partnership strategy for PDS0101.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.